Background: Corneal opacity is a major cause of vision impairment resulting from trauma and wounds. Corticosteroids are effective in reducing fibrosis; however, their use is associated with an increased risk of intraocular pressure (IOP). Losartan, an angiotensin II antagonist and TGFβ pathway inhibitor, has demonstrated antifibrotic potential in topical applications; however, its safety regarding IOP changes in animal models remains unclear. Objectives: This study aimed to evaluate the effects of topical losartan, betamethasone, and their combination on IOP in a rat model of partial-thickness corneal injury over a four-week treatment period. Methods: Twenty-four adult male Wistar rats were randomly assigned to four groups (n=6): negative control (BSS), topical Losartan (0.08%), topical betamethasone (0.1%), and a combination of losartan + betamethasone. Partial-thickness corneal injury was induced on day 0, and treatments were administered from day 4 onward. Each treatment consisted of six daily doses (every two hours) applied to the right eye for 30 days. At the end of the study, IOP in both eyes was measured using an iCare tonometer in three sets of six readings (a total average of 18 readings per eye). Data were reported as mean ± standard deviation and analyzed statistically for comparisons between groups and between treated and untreated eyes. Results: Mean IOP across the losartan, betamethasone, combination, and control groups showed no significant differences (p > 0.05). Similarly, no significant differences were observed between the treated (right) and untreated (left) eyes within any group (p > 0.05). Conclusions This study demonstrated that one-month application of topical Losartan, Betamethasone, and their combination for the treatment of opacity caused by partial-thickness corneal injury in rats has no significant impact on intraocular pressure.

کلمات کلیدی